Potential Roles of Glucagon-Like Peptide-1 and Its Analogues in Dementia Targeting Impaired Insulin Secretion and Neurodegeneration

Sidharth Mehan,Sonalika Bhalla,Ehraz Mehmood Siddiqui,Nidhi Sharma,Ambika Shandilya,Andleeb Khan

DOI: https://doi.org/10.2147/DNND.S247153

2022-03-07

Degenerative Neurological and Neuromuscular Disease

Abstract:Sidharth Mehan, 1 Sonalika Bhalla, 1 Ehraz Mehmood Siddiqui, 1 Nidhi Sharma, 1 Ambika Shandilya, 1 Andleeb Khan 2 1 Neuropharmacology Division, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India; 2 Department of Pharmacology & Toxicology, College of Pharmacy, Jazan University, Jazan, Kingdom of Saudi Arabia Correspondence: Sidharth Mehan, Neuropharmacology Division, Department of Pharmacology, ISF College of Pharmacy, Moga, 142001, Punjab, India, Tel +91 8059889909 ; +91 9461322911, Email ; Dementia is a chronic, irreversible condition marked by memory loss, cognitive decline, and mental instability. It is clinically related to various progressive neurological diseases, including Parkinson's disease, Alzheimer's disease, and Huntington's. The primary cause of neurological disorders is insulin desensitization, demyelination, oxidative stress, and neuroinflammation accompanied by various aberrant proteins such as amyloid-β deposits, Lewy bodies accumulation, tau formation leading to neurofibrillary tangles. Impaired insulin signaling is directly associated with amyloid-β and α-synuclein deposition, as well as specific signaling cascades involved in neurodegenerative diseases. Insulin dysfunction may initiate various intracellular signaling cascades, including phosphoinositide 3-kinase (PI3K), c-Jun N-terminal kinases (JNK), and mitogen-activated protein kinase (MAPK). Neuronal death, inflammation, neuronal excitation, mitochondrial malfunction, and protein deposition are all influenced by insulin. Recent research has focused on GLP-1 receptor agonists as a potential therapeutic target. They increase glucose-dependent insulin secretion and are beneficial in neurodegenerative diseases by reducing oxidative stress and cytokine production. They reduce the deposition of abnormal proteins by crossing the blood-brain barrier. The purpose of this article is to discuss the role of insulin dysfunction in the pathogenesis of neurological diseases, specifically dementia. Additionally, we reviewed the therapeutic target (GLP-1) and its receptor activators as a possible treatment of dementia. Keywords: dementia, insulin signaling, neurodegeneration, GLP-1 activators Dementia is an irreversible, slowly progressive syndrome characterized by cognitive decline and memory impairment due to anatomical changes in the brain. 1 It is primarily associated with Alzheimer's disease, vascular dementia, frontotemporal dementia, Creutzfeldt-Jakob disease, mixed dementia, Lewy body dementia, Parkinson-related dementia, and Huntington's disease. 2 More than 55 million people worldwide have dementia, with 10 million new cases diagnosed each year. Alzheimer's disease causes 60–70% of all dementia cases. 3 Most surveys conducted globally found annual incidence rates of 10–15 per 100,000 people, and its prevalence could reach 2% in people aged 65 and up. 4 Dementia is now the seventh leading cause of death worldwide and has become one of the most common causes of old age disability and dependency. Dementia is classified into three stages based on severity and progression: early, middle, and late stages. It typically begins with forgetfulness, but patients may develop difficulties with recognition and aggression as the disease progresses. 1 Dementia has significant physical, psychological, social, and economic consequences that affect dementia patients, caregivers, families, and society. 5 It affects memory, thinking, orientation, comprehension, calculation, learning capacity, language, and judgment does not affect consciousness. Changes in mood, emotional control, behaviour, or motivation are frequently associated with and occasionally precede cognitive function impairment. 1 Dementia, associated with several neurodegenerative diseases such as Huntington's disease (HD), causes genetic defects that decline a patient's memory, thinking, and emotional state. 6 Tau protein accumulation around brain cells causes the formation of neurofibrillary tangles via amyloid-β protein. Plaques may cause Alzheimer's disease, or they may be a byproduct of the disease process and related to dementia. 2 Additionally, when an abnormal infectious protein called a prion is expressed and accumulated in the brain at high levels, it causes irreversible damage to neuronal cells. This condition is known as Creutzfeldt-Jakob dementia, characterized by unusual anatomical changes in the brain, particularly in the frontal and temporal lobes. 7 Frontotemporal dementia is marked by atrophy in these brain areas and is associated with personality, behaviour, and language. 8 In Parkinson's disease, α-syn abnormal accumulation is found in substantia nigra neur -Abstract Truncated-

English Else